MTBVAC, tuberculosis vaccine
Tuberculosis remains one of the most lethal communicable diseases in the world, with 10 million new cases and 1.5 million deaths per year. The figures in the WHO report for 2016 place this disease for the first time with the highest mortality rate worldwide, surpassing AIDS.
For almost 100 years, BCG (Bacillus Calmette-Guerin) has been the only vaccine against tuberculosis that protects children against the most serious forms of this disease. However, it has been shown that BCG is no longer effective against the most contagious and widespread disease, the pulmonary tuberculosis.
The lack of efficacy in the prevention of pulmonary tuberculosis in adolescents and adults, it makes necessary the urgent need to obtain a new one that replaces the only and current BCG. Therefore the development of new vaccines capable of preventing the respiratory forms of TB is essential for the control of their spread. Within the current portfolio of vaccines under development worldwide against tuberculosis, our MTBVAC vaccine is one of the strongest candidates and most promising in the opinion of experts worldwide.
MTBVAC, is a live attenuated vaccine of M. tuberculosis (Mycobacterium tuberculosis) designed by the genetic research group of Dr. Carlos Martin Montañés of the Department of Microbiology at the University of Zaragoza and Brigitte Gicquel at the Institut Pasteur of Paris.
MTBVAC is currently in Phase 2 of clinical trials in both newborns and adults.
Biofabri is responsible for the manufacture of MTBVAC as a live attenuated lyophilized vaccine and aims to license MTBVAC against tuberculosis in both, adults and newborns.
The results obtained so far after completing phase 1a and 1b, show equal or greater safety in addition to a greater immune response against this terrible disease.
The MTBVAC vaccine is currently in Phase 2 clinical trials with both newborns and adults in South Africa, one of the largest endemic countrie.
These two parallel clinical trials, have the financial support of two prestigious international organizations, the Cooperation of Europe and the Developing Countries on clinical trials (EDCTP, acronym in English) and the Medical Research Program Directed by Congress (CDMRP, acronyms in English), from the US along with the collaboration of AERAS, a North American non-profit organization dedicated to the development of new vaccines against tuberculosis. AERAS has the support of the relevant financial support of the Bill and Melinda Gates Foundation (BMGF, acronym in English).